Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

Ahmet Emre Eşkazan

doi:10.1111/bcp.13637

Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

Br J Clin Pharmacol. 2018 Aug;84(8):1635-1638. doi: 10.1111/bcp.13637. Epub 2018 Jun 3.

Author

Ahmet Emre Eşkazan¹

Affiliation

¹ Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.

No abstract available

Keywords: chronic myeloid leukaemia; deep molecular response; discontinuation; early molecular response; treatment-free remission; tyrosine kinase inhibitor.

Publication types

Editorial

MeSH terms

Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins c-abl / antagonists & inhibitors
Proto-Oncogene Proteins c-bcr / antagonists & inhibitors
Randomized Controlled Trials as Topic*
Remission Induction / methods
Time Factors
Treatment Outcome
Withholding Treatment

Substances

Protein Kinase Inhibitors
ABL1 protein, human
Proto-Oncogene Proteins c-abl
BCR protein, human
Proto-Oncogene Proteins c-bcr